Sign In
Free Newsletter
Reprocell receives funding from MD Stem Cell Research Fund
Reprocell, a Yokohama, Japan-based company that produces clinically relevant human induced pluripotent stem cells (hiPSCs) from its laboratory in Beltsville, received grant money from the Maryland Stem Cell Research Fund to further commercialization capabilities.
Terms of the grants were not disclosed.
These hiPSCs are generated from healthy donors that have been screened for eligibility using the questionnaire established by the US Food & Drug Administration. Further viral testing is performed to satisfy the requirements of FDA, European Medicines Agency (EMA) and Pharmaceutical and Medical Devices Agency (PMDA) of Japan.
The first grant will help Reprocell offer two GMP grade cell lines in the next eight to 12 months for commercialization. These products will be tested for quality and ready for off-the-shelf distribution and further differentiation internally, by other companies in Maryland and worldwide.
The second grant will help the company increase the capacity from generating two MCBs per year to generating four to six MCBs per year by adding more incubators and processing chambers to the existing enclosed GMP system. Utilizing these enhancements, Reprocell can also provide GMP differentiation and gene editing services.
This grant from the MSCRF under its manufacturing assistance program is a direct match grant where Reprocell will match funds provided by MSCRF dollar-to-dollar.
